- Home
- LIXT vs IBIO Comparison
LIXT vs IBIO Comparison
Compare LIXT & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- IBIO
- Stock Information
- Founded
- LIXT 2005
- IBIO 2008
- Country
- LIXT United States
- IBIO United States
- Employees
- LIXT N/A
- IBIO N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- IBIO Health Care
- Exchange
- LIXT Nasdaq
- IBIO Nasdaq
- Market Cap
- LIXT 12.4M
- IBIO 11.9M
- IPO Year
- LIXT N/A
- IBIO N/A
- Fundamental
- Price
- LIXT $4.85
- IBIO $0.57
- Analyst Decision
- LIXT
- IBIO Strong Buy
- Analyst Count
- LIXT 0
- IBIO 2
- Target Price
- LIXT N/A
- IBIO $5.50
- AVG Volume (30 Days)
- LIXT 193.9K
- IBIO 400.1K
- Earning Date
- LIXT 08-07-2025
- IBIO 09-19-2025
- Dividend Yield
- LIXT N/A
- IBIO N/A
- EPS Growth
- LIXT N/A
- IBIO N/A
- EPS
- LIXT N/A
- IBIO N/A
- Revenue
- LIXT N/A
- IBIO $375,000.00
- Revenue This Year
- LIXT N/A
- IBIO $81.33
- Revenue Next Year
- LIXT N/A
- IBIO N/A
- P/E Ratio
- LIXT N/A
- IBIO N/A
- Revenue Growth
- LIXT N/A
- IBIO 650.00
- 52 Week Low
- LIXT $0.64
- IBIO $0.56
- 52 Week High
- LIXT $5.14
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- LIXT 64.92
- IBIO 24.65
- Support Level
- LIXT $4.20
- IBIO $0.56
- Resistance Level
- LIXT $5.06
- IBIO $0.78
- Average True Range (ATR)
- LIXT 0.44
- IBIO 0.03
- MACD
- LIXT -0.02
- IBIO -0.01
- Stochastic Oscillator
- LIXT 80.79
- IBIO 6.24
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.